Last reviewed · How we verify
L-Methionine (METHIONINE)
At a glance
| Generic name | METHIONINE |
|---|---|
| Drug class | methionine |
| Target | S-ribosylhomocysteine lyase |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Single-Center Phase II Double-Blind Trial of SAMe to Prevent Liver Cancer in MASLD-Related Cirrhosis (PHASE2)
- Safety and Efficacy of Faricimab in Patients With NPDR (PHASE2)
- SAMe in Prevention of Oxaliplatin-associated Liver Injury (PHASE2)
- Essential Amino Acids and Parkinsons Disease (PHASE1)
- Methionine for CaPhos Stone (NA)
- A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma (PHASE2)
- Proof of Concept Creatine Supplementation for Homocystinuria Study (NA)
- Methionine Requirements During Healthy Human Pregnancy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-Methionine CI brief — competitive landscape report
- L-Methionine updates RSS · CI watch RSS